The GLP-1 (glucagon-like peptide-1) class has become the fastest-growing segment of the peptide market, driven by demand for metabolic and weight-management research and an expanding pipeline of multi-receptor agonists.
Key molecules
- Semaglutide — an established GLP-1 receptor agonist available from numerous API suppliers
- Tirzepatide — a dual GIP/GLP-1 receptor agonist
- Retatrutide — a triple GIP/GLP-1/glucagon agonist in late-stage development
- Cagrilintide — an amylin analog frequently combined with GLP-1 agonists (e.g., Cagrisema)
Supply landscape
API-grade GLP-1 peptides are offered by both large manufacturers and smaller research vendors. Pricing varies dramatically with purity grade, order volume, and whether the buyer requires GMP documentation. Wholesale buyers should request complete impurity profiles, residual solvent data, and stability studies.
Quality considerations
GLP-1 peptides are long, complex sequences that are harder to synthesize than short research peptides. Verify purity by both HPLC and mass spectrometry, confirm peptide content versus salt weight, and be alert to counterfeit or relabeled API entering the market through unofficial channels.
Outlook
Analysts expect continued double-digit growth as combination therapies and oral formulations advance. For buyers, this means more suppliers but also greater variance in quality—making documentation and verification more important, not less.